Deep Data Dive: Highlights From ASCO 2024 on the Treatment of High-Risk BCG-Unresponsive NMIBC : Episode 8
Opinion
Video
Results of the CORE-001 Trial: 24-Month Complete Response Rate and Duration of Response
Experts discuss the results of the CORE-001 Trial.
Video Player is loading.
Video content above is prompted by the following questions:
- In the CORE-001 trial, what were the results for the primary endpoint of complete response at 24 months as well as the secondary endpoint of duration of response? What is notable about these results?
- How do these results compare to those associated with other FDA-approved therapies and other investigational drugs?
- What was the overall cystectomy-free survival rate, and what was this rate among patients who experienced a complete response?
- Were there other notable efficacy outcomes?
Related Videos
Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
Expert discusses the NMIBC trials landscape
John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Study data point to gender disparities in oncology research citations
Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
Expert describes implications of neoadjuvant durvalumab approval in MIBC
Related Content
